| Title |
Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, July 2015
|
| DOI | 10.1007/s00259-015-3115-5 |
| Pubmed ID | |
| Authors |
Konstantinos Chiotis, Stephen F. Carter, Karim Farid, Irina Savitcheva, Agneta Nordberg, for the Diagnostic Molecular Imaging (DiMI) network and the Alzheimer’s Disease Neuroimaging Initiative |
| Abstract |
Several radiotracers that bind to fibrillar amyloid-beta in the brain have been developed and used in various patient cohorts. This study aimed to investigate the comparability of two amyloid positron emission tomography (PET) tracers as well as examine how age affects the discriminative properties of amyloid PET imaging. Fifty-one healthy controls (HCs), 72 patients with mild cognitive impairment (MCI) and 90 patients with Alzheimer's disease (AD) from a European cohort were scanned with [11C]Pittsburgh compound-B (PIB) and compared with an age-, sex- and disease severity-matched population of 51 HC, 72 MCI and 84 AD patients from a North American cohort who were scanned with [18F]Florbetapir. An additional North American population of 246 HC, 342 MCI and 138 AD patients with a Florbetapir scan was split by age (55-75 vs 76-93 y) into groups matched for gender and disease severity. PET template-based analyses were used to quantify regional tracer uptake. The mean regional uptake patterns were similar and strong correlations were found between the two tracers across the regions of interest in HC (ρ = 0.671, p = 0.02), amyloid-positive MCI (ρ = 0.902, p < 0.001) and AD patients (ρ = 0.853, p < 0.001). The application of the Florbetapir cut-off point resulted in a higher proportion of amyloid-positive HC and a lower proportion of amyloid-positive AD patients in the older group (28 and 30 %, respectively) than in the younger group (19 and 20 %, respectively). These results illustrate the comparability of Florbetapir and PIB in unrelated but matched patient populations. The role of amyloid PET imaging becomes increasingly important with increasing age in the diagnostic assessment of clinically impaired patients. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 75 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 17% |
| Student > Ph. D. Student | 11 | 14% |
| Student > Master | 10 | 13% |
| Other | 10 | 13% |
| Student > Doctoral Student | 4 | 5% |
| Other | 10 | 13% |
| Unknown | 18 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 32% |
| Neuroscience | 7 | 9% |
| Psychology | 7 | 9% |
| Agricultural and Biological Sciences | 5 | 7% |
| Physics and Astronomy | 2 | 3% |
| Other | 10 | 13% |
| Unknown | 21 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2015.
All research outputs
#2,983,664
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#267
of 3,083 outputs
Outputs of similar age
#38,154
of 264,828 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#1
of 62 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,828 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.